Opinion|Videos|February 17, 2025
The Role of Private Label Agreements in Enhancing Access to Biosimilars
Panelists discuss how private label agreements facilitate biosimilar market entry by allowing manufacturers to collaborate on branding, distribution, and market access, ultimately expanding treatment options and potentially reducing health care costs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of private label agreements and how can they enhance access to biosimilars?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq
2
Senate Democrats Outline Drug Pricing Agenda to Cut Patient Costs
3
Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries
4
ACOs Improve Primary, Preventive Care Delivery for Medicare Beneficiaries
5
